Sameep Sehgal

Dr. Sameep Sehgal

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SSSameep Sehgal
Sameep Sehgal
APAditi Patel
Aditi Patel
SCSoumya Chatterjee
Soumya Chatterjee
AFAnthony P Fernandez
Anthony P Fernandez
CFCarol Farver
Carol Farver
KHKristin B Highland
Kristin B Highland

1 July 2018 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SRShine Raju
Shine Raju
RJRanjit Joseph
Ranjit Joseph
SSSameep Sehgal
Sameep Sehgal
Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunotherapy for advanced non-small cell lung cancer (NSCLC) has resulted in a new paradigm of treatment options resulting in improved survival and response rates and has a less severe yet unique toxicity profile when compared to chemotherapy. PD-1 inhibitors, nivolumab and pembrolizumab, and PD-L1 inhibitor, atezolizumab, are currently approved by regulatory authorities for the treatment of advanced NSCLC. This article provides a detailed review of these newer agents, their mechanism of action, side-effect profile, therapeutic indications and current evidence supporting their use in the management of NSCLC.

29 May 2019 in Lung
Verified
Journal Article
Closed access
PDF file
SGSTep-count using an Accelerometer for Monitoring PAH—STAMP Study group
STep-count using an Accelerometer for Monitoring PAH—STAMP Study group
SSSameep Sehgal
Sameep Sehgal
ACAnanda Chowdhury
Ananda Chowdhury
FRFadi Rabih
Fadi Rabih
AGAbhishek Gadre
Abhishek Gadre
KHKristin B. Highland
Kristin B. Highland

1 May 2019 in Respiratory Medicine
Verified
Journal Article
Closed access
SSSameep Sehgal
Sameep Sehgal
BSBronwyn Small
Bronwyn Small
KHKristin B. Highland
Kristin B. Highland

20 January 2021 in Transplant International
Verified
Journal Article
Closed access
PDF file
OTOlga A. Timofeeva
Olga A. Timofeeva
JCJason Choe
Jason Choe
MAMohamed Alsammak
Mohamed Alsammak
EYEdward J. Yoon
Edward J. Yoon
SGSteven S. Geier
Steven S. Geier
JBJames C. Brown
James C. Brown
Antibody‐Mediated Rejection (AMR) due to donor‐specific antibodies (DSA) is associated with poor outcomes after lung transplantation. Currently there are no guidelines regarding the selection of treatment protocols. We studied how DSA characteristics including titers, C1q, and mean fluorescence intensity (MFI) values in undiluted and diluted sera may predict a response to therapeutic plasma exchange (TPE) and inform patient prognosis after treatment. Among 357 patients consecutively transplanted without detectable pre‐existing DSAs between 01/01/16 and 12/31/18, 10 patients were treated with a standardized protocol of five TPE sessions with IVIG. Based on DSA characteristics after treatment, all patients were divided into three groups as responders, partial responders, and non‐responders. Kaplan‐Meier Survival analyses showed a statistically significant difference in patient survival between those groups (P= 0.0104). Statistical analyses showed that MFI in pre‐TPE 1:16 diluted sera was predictive of a response to standardized protocol (R2=0.9182) and patient survival (P=0.0098). Patients predicted to be non‐responders who underwent treatment with a more aggressive protocol of 8 TPE sessions with IVIG and bortezomib showed improvements in treatment response (P=0.0074) and patient survival (P= 0.0253). Dilutions may guide clinicians as to which patients would be expected to respond to a standards protocol or require more aggressive treatment.

4 May 2020 in Current Pulmonology Reports
Verified
Journal Article
Closed access
PDF file
MZMatthew Zheng
Matthew Zheng
RMRobert M. Marron
Robert M. Marron
SSSameep Sehgal
Sameep Sehgal